Centogene B V is a diagnostics & research business based in the US. Centogene B V shares (CNTG) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.09 – a decrease of 33.15% over the previous week. Centogene B V employs 384 staff and has a trailing 12-month revenue of around $48.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.09 |
|---|---|
| 52-week range | $0.06 - $1.35 |
| 50-day moving average | $0.38 |
| 200-day moving average | $0.73 |
| Wall St. target price | $1.52 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0955 from 2024-11-19
| 1 week (2024-11-15) | -11.74% |
|---|---|
| 1 month (2024-10-22) | -20.42% |
| 3 months (2024-08-22) | -37.46% |
| 6 months (2024-05-22) | -75.94% |
| 1 year (2023-11-22) | -92.04% |
|---|---|
| 2 years (2022-11-22) | -87.27% |
| 3 years (2021-11-22) | 8.875 |
| 5 years (2019-11-22) | 13.35 |
| Revenue TTM | $48.5 million |
|---|---|
| Gross profit TTM | $35.9 million |
| Return on assets TTM | -26.76% |
| Return on equity TTM | -1375.33% |
| Profit margin | -73.21% |
| Book value | $-0.87 |
| Market Capitalization | $9.4 million |
TTM: trailing 12 months
We're not expecting Centogene B V to pay a dividend over the next 12 months.
Over the last 12 months, Centogene B V's shares have ranged in value from as little as $0.055 up to $1.345. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Centogene B V's is -0.672. This would suggest that Centogene B V's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Centogene B V has bucked the trend.
Centogene N. V. , together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2. 0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports.
The $500 Axos Bank bonus is now expired, but you can still earn $50 per qualifying referral, plus up to $400 with a new business account.
Find out if Priority Plus Financial’s advertised loans are worth it or just a sales hook.
Where to get a holiday loan in 2024 and whether it makes sense for you.
Modak has no monthly fee, but it’s slim on features. Greenlight starts at $5.99 but is a value for big families.
Get the capital your business needs to grow with repayments that adapt to your revenue.
We’ve compared the best cash advance apps for quick cash — find the right one for your needs.
A review of Beyond Finance, a company that offers debt settlement and consolidation loans.
1. Make a budget 2. Create a savings plan 3. Automate savings 4. Pay yourself first 5. Use a high-yield account 6. Do a savings challenge…
To save $10K: 1. Automate savings 2. Invest 3. Budget 4. Open a high-yield savings account 5. Cut down on spending 6. Pay off debt…
A review of Arrowhead Advance, a tribal lender that charges interest rates up to 830% and has numerous bad reviews.